Jennifer Petter
Founder & Chief Scientific Officer Arrakis Therapeutics Inc.
Seminars
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics
• How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines
• How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets and attract strategic capital
• What trends can be identified from recent investments, M&A activity and deal structures to inform future strategies in RNA therapeutics
While splice modulation has paved the way for RNA-targeted therapeutics, the next frontier lies in unlocking the therapeutic potential of directly targeting RNA. This workshop explores innovative strategies exploring covalently binding RNA, bivalent compounds inducing proximity between RNA and effector molecules, and the untapped opportunity of targeting long non-coding RNAs.
Attendees will cover:
• Exploring covalent binders and proximity-inducing molecules to introduce functional outcomes into RNA targeted strategies
• Developing and validating a novel LC/MS-based chromatography method to quantify covalent reactivity with nucleotides/nucleobases, enabling comparison of RNA- vs protein-targeted electrophiles
• Developing lncRNA targeted small molecules to inhibit aggressive cancer phenotypes similarly to knock-out models
